Illumina, Inc. (ILMN): financials, SEC filings and peers
Illumina, Inc. (ILMN) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in San Diego, California.
It was founded in 1998 and joined the S&P 500 on September 21, 2026.
Its fiscal year ends in January, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Laboratory Analytical Instruments”.
Illumina, Inc. at a glance
- Revenue (12 months)
- $4.5B
- Revenue growth
- +5.8%
- Operating margin
- 21.2%
- Net income (12 months)
- $895M
- Free cash flow (12 months)
- $1.1B
- Cash
- $1.3B
- Debt
- —
- Diluted EPS (12 months)
- $5.81
Twelve months to September 27, 2026, from the 10-Q filed October 30, 2026.
Latest twelve months
Over the twelve months to September 27, 2026, Illumina, Inc. reported revenue of $4.5 billion, about the same as a year earlier (+5.8%).
Its operating margin was 21.2%, up 3.0 percentage points from a year earlier: for every $100 of sales, about $21 was left as operating profit.
Net income was $895 million (19.7% of revenue), 27.5% higher than a year earlier.
Operating cash flow was $1.2 billion and capital spending $173 million, leaving free cash flow of $1.1 billion (23.3% of revenue).
At the end of the period it held $1.3 billion in cash and not reported in debt, a net cash position of $1.3 billion.
Five-year trend
- Revenue went from $3.2 billion in fiscal 2021 to $4.3 billion in fiscal 2025, about 6.0% a year.
- Operating margin has been steady, around 18.6%.
- Free cash flow was positive in each of the last 6 fiscal years.
- Illumina, Inc. reported a net loss in 3 of the last 6 fiscal years.
| Fiscal year | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.5B | $4.6B | $4.5B | $4.4B | $4.3B |
| Revenue growth | 39.7% | 1.3% | -1.7% | -2.9% | -0.7% |
| Operating margin | -2.7% | -91.2% | -23.7% | -19.1% | 18.6% |
| Net income | $762M | −$4.4B | −$1.2B | −$1.2B | $850M |
| Free cash flow | $337M | $106M | $283M | $709M | $931M |
| Diluted EPS | $5.04 | $-28.00 | $-7.34 | $-7.69 | $5.45 |
Fiscal years as reported in Illumina, Inc.’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed October 30, 2026 — quarterly report
- 8-K filed October 29, 2026 — Earnings results
- 8-K filed October 13, 2026 — Material agreement; New debt obligation
- 8-K filed August 17, 2026 — Other event
- 8-K filed August 13, 2026 — Material agreement; Agreement terminated
- 8-K filed August 12, 2026 — Other event
- 8-K filed August 7, 2026 — Other event
- 10-Q filed July 31, 2026 — quarterly report
Companies like Illumina, Inc.
Other S&P 500 companies in Life Sciences Tools & Services:
- AAgilent TechnologiesSanta Clara, California
- CRLCharles River LaboratoriesWilmington, Massachusetts
- DHRDanaher CorporationWashington, D.C.
- IQVIQVIADurham, North Carolina
- MTDMettler ToledoColumbus, Ohio
- TECHBio-TechneMinneapolis, Minnesota
- TMOThermo Fisher ScientificWaltham, Massachusetts
- WATWaters CorporationMilford, Massachusetts
More from Health Care
Questions about Illumina, Inc.
Is Illumina, Inc.'s revenue growing?
Yes. Revenue for the twelve months to September 27, 2026 was $4.5 billion, up 5.8% from a year earlier, according to its SEC filings.
Is Illumina, Inc. profitable?
Yes. It earned $895 million in net income over the twelve months to September 27, 2026, a net margin of 19.7%.
When did Illumina, Inc. last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on October 30, 2026.
Which companies are similar to Illumina, Inc.?
In the S&P 500, Illumina, Inc. is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), IQVIA (IQV), Mettler Toledo (MTD) are in the same group.
Understand the numbers
Source: Illumina, Inc.’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.